And supplements marketed as boosting GLP-1 levels lack clinical evidence that they work in humans, at least by any measure that parallels the effects of prescription GLP-1 drugs, said Pieter Cohen, an associate professor of medicine at Harvard Medical School
PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations
Topical applications appear generally well-tolerated in small studies, but systemic safety, long-term effects, and drug interactions remain inadequately characterized
Michael Clerveus, MD , ensuring safe dosing, accountability, and personalized medical oversight
The most widely known GLP-1 is semaglutide, sold under the brand names Ozempic and Wegovy, which is associated with roughly 15% total body weight loss